研究室の業績

2023年の業績

  1. Konno S, Tanaka M, Mizuguchi T, Toyokai H, Taguchi A, Taniguchi A, Hayashi Y. Peptide mixed phosphonates for covalent complex formation with thioesterases in nonribosomal peptide synthetases. J. Pept. Sci. 2023, e3532.

  2. Mukaiyama M, Uchiyama C, Fukuda A, Nakazawa Y, Kuramochi Y, Shibata Y, Konno S, Muguruma K, Matsugaki N, Asari T, Ogawa K, Taguchi A, Takayama K, Taniguchi A, Nagumo Y, Senda T, Hayashi Y, Usui T. X-Ray Conformation and Structure-Activity Relationships of MA026, a Reversible Tight Junction Opener. J. Med. Chem. 2023, 66, 8717–8724.

  3. Murakami H, Fujikawa Y, Mori M, Mosu N, Taguchi A, Hayashi Y, Inoue H, Kamisuki S. Development of a novel fluorogenic assay method for screening inhibitors of bovine leukemia virus protease and identification of mitorubrinic acid as an anti-BLV compound. Biosci. Biotechnol. Biochem. 2023, 87, 946–953.

  4. Shida H, Taguchi A, Konno S, Takayama K, Taniguchi A, Hayashi Y. Establishment of One-Pot Disulfide-Driven Cyclic Peptide Synthesis with a 3-Nitro-2-pyridinesulfenate. Chem. Pharm. Bull. 2023, 71, 435–440.

  5. Okamoto H, Murano SA, Ikekawa K, Katsuyama M, Konno S, Taguchi A, Takayama K, Taniguchi A, Hayashi Y. Inactivation of myostatin by photooxygenation using functionalized d-peptides. RSC Med. Chem. 2023, 14, 386–392.

  6. Michiue K, Takayama K, Taniguchi A, Hayashi Y, Kogure K. Increasing Skeletal Muscle Mass in Mice by Non-Invasive Intramuscular Delivery of Myostatin Inhibitory Peptide by Iontophoresis. Pharmaceuticals 2023, 16, 397.

2022年度の業績

  1. Hanada, K., Fukasawa, K., Hinata, H., Imai, S., Takayama, K., Hirai, H., Ohfusa, R., Hayashi, Y., Itoh, F. Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model. Cancer Sci. 2022,113, 3547–3557.

  2. Cui, Y.; Taguchi, A.; Shida, H.; Konno, S.; Takayama, K.; Taniguchi, A.; Hayashi, Y. Chemical synthesis of an HIV-1 protease analog with some amides in a polypeptide main chain replaced by disulfide bonds. Bull. Chem. Soc. Jpn. 2022, 95, 1156-1162.

  3. Otani, Y.; Taguchi, A.; Hamada, K.; Hayashi, Y.; Yamaguchi, Y.; Baba, H. Influence of novel readthrough agents on myelin protein zero translation in the peripheral nervous system. Neuropharmacology 2022, 211, 109059.

  4. Takayama, K.; Hitachi, K.; Okamoto, H.; Saitoh, M.; Odagiri, M.; Ohfusa, R.; Shimada, T.; Taguchi, A.; Taniguchi, A.; Tsuchida, K.; Hayashi, Y. Development of Myostatin Inhibitory d-Peptides to Enhance the Potency, Increasing Skeletal Muscle Mass in Mice. ACS Med. Chem. Lett. 2022, 13, 492–498.

2021年の業績

  1. Asari, T.; Ikeyama, H.; Taguchi, A.; Taniguchi, A.; Hayashi, Y.; Takayama, K. Proposal for the binding mode of the 23-mer inhibitory peptide to myostatin. Bioorg. Med. Chem. 2021, 40, 116181.

  2. Hoshi, M.; Shiino, S.; Gomi, A.; Sakata, K.; Konno, S.; Hayashi, Y.; Kojima, M. In silico Design of Inhibitor Against SARS-CoV-2 Protease by Docking Simulation and ADMET PredictionBioimages 2021, 29, 11–21.

  3. Konno, S.; Kobayashi, K.; Senda, M.; Funai, Y.; Seki, Y.; Tamai, T.; Schäkel, L.; Sakata, K.; Pillaiyar, T.; Taguchi, A.; Taniguchi, A.; Gütschow, M.; Müller, C. E.; Takeuchi, K.; Hirohama, M.; Kawaguchi, A.; Kojima, M.; Senda, T.; Shirasaka, Y.; Kamitani, W.; Hayashi, Y. 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV‐2 Agents. J. Med. Chem. 2021, 65, 2926-2939.

  4. Kobayakawa, T.; Azuma, C.; Watanabe, Y.; Sawamura, S.; Taniguchi, A.; Hayashi, Y.; Tsuji, K.; Tamamura, H. Development of Methods for Convergent Synthesis of Chloroalkene Dipeptide Isosteres and Its Application. J. Org. Chem. 2021, 86, 5091–5101. 

  5. Sasaki, K.; Muguruma, K,; Osawa, R.; Fukuda, A.; Taniguchi, A.; Hayashi, Y.; Kishimura, A.; Mori, T.; Katayama, Y. Synthesis and biological evaluation of a novel, monocyclic Fc-binding antibody-recruiting molecule for cancer immunotherapy. RSC Med. Chem. 2021, 12, 406–409.

  6. Kobayashi, K.; Taguchi, A.; Cui, Y.; Shida, H.; Muguruma, K.; Takayama, K.; Taniguchi, A.; Hayashi, Y. “On-resin” disulfide peptide synthesis with methyl 3-nitro-2-pyridinesulfenate. Eur. J. Org. Chem. 2021, 956–963.

  7. Muguruma, K.; Osawa, R.; Fukuda, A.; Ishikawa, N.; Fujita, K.; Taguchi, A.; Takayama, K.; Taniguchi, A.; Ito, Y.; Hayashi, Y. Development of a high‐affinity antibody‐binding peptide for site‐specific modification. ChemMedChem 2021, 16, 1814–1821.

  8. Uchiyama, C.; Fukuda, A.; Mukaiyama, M.; Nakazawa, Y.; Kuramochi, Y.; Muguruma, K.; Arimoto, M.; Ninomiya, A.; Kako, K.; Katsuyama, Y.; Konno, S.; Taguchi, A.; Takayama, K.; Taniguchi, A.; Nagumo, Y.; Usui, T.; Hayashi, Y. Structural revision of natural cyclic depsipeptide MA026 established by total synthesis and biosynthetic gene cluster analysis. Angew. Chem. Int. Ed. 2021, 60, 8792–8797.

  9. Okamoto, H.; Taniguchi, A.; Usami, S.; Katsuyama, M.; Konno, S.; Taguchi, A.; Takayama, K.; Hayashi, Y. Development of functionalized peptides for efficient inhibition of myostatin by selective photooxygenation. Org. Biomol. Chem. 2021, 19, 199–207.

2020年の業績

  1. Akihiro Taguchi, Kiyotaka Kobayashi, Yan Cui, Kentaro Takayama, Atsuhiko Taniguchi, Yoshio Hayashi, Disulfide-driven cyclic peptide synthesis of human endothelin-2 with a solid-supported Npys-Cl, J. Org. Chem. (2020) 85, 1495-1503. doi: 10.1021/acs.joc.9b02362

  2. Mariko Saitoh, Kentaro Takayama, Keisuke Hitachi, Akihiro Taguchi, Atsuhiko Taniguchi, Kunihiro Tsuchida, Yoshio Hayashi, Discovery of a follistatin-derived myostatin inhibitory peptide, Bioorg. Med. Chem. Lett., 2020, 30, 126892. doi: 10.1016/j.bmcl.2019.126892

  3. Akiko Tanaka, Kentaro Takayama, Tomoyuki Furubayashi, Kenji Mori, Yuki Takemura, Mayumi Amano, Chiaki Maeda, Daisuke Inoue, Shunsuke Kimura, Akiko Kiriyama, Hidemasa Katsumi, Mikiya Miyazato, Kenji Kangawa, Toshiyasu Sakane, Yoshio Hayashi, Akira Yamamoto, Transnasal delivery of the peptide agonist specific to neuromedin-U receptor 2 to the brain for the treatment of obesity, Mol. Pharmaceutics (2020) 17, 32-39. doi: 10.1021/acs.molpharmaceut.9b00571

2019年の業績

  1. Cédric Rentier, Kentaro Takayama, Mariko Saitoh, Akari Nakamura, Hiroaki Ikeyama, Akihiro Taguchi, Atsuhiko Taniguchi, Yoshio Hayashi, Design and synthesis of potent myostatin inhibitory cyclic peptides, Bioorg. Med. Chem. (2019) 27, 1437-1443.
  2. Kentaro Takayama, Tomo Asari, Mariko Saitoh, Kei Nirasawa, Eri Sasaki, Yoshimi Roppongi, Akari Nakamura, Yusuke Saga, Takahiro Shimada, Hiroaki Ikeyama, Akihiro Taguchi, Atsuhiko Taniguchi, Yoichi Negishi, and Yoshio Hayashi, Chain-shortened myostatin inhibitory peptides improve grip strength in mice, ACS Med. Chem. Lett. (2019) 10, 985-990.
  3. Hideyuki Okamoto, Atsuhiko Taniguchi, Shoya Usami, Akihiro Taguchi, Kentaro Takayama and Yoshio Hayashi, Inactivation of myostatin by photo-oxygenation using catalyst-functionalized peptides, Chem. Commun. (2019) 55, 9108-9111.
  4. Kyohei Muguruma, Konomi Fujita, Akane Fukuda, Satoshi Kishimoto, Soichiro Sakamoto, Risako Arima, Mayu Ito, Mayu Kawasaki, Shogo Nakano, Sohei Ito, Kanade Shimizu, Akihiro Taguchi, Kentaro Takayama, Atsuhiko Taniguchi, Yuji Ito, Yoshio Hayashi, Kinetics-based structural requirements of human immunoglobulin G binding peptides, ACS Omega (2019) 4, 14390-14397.
  5. Kyohei Muguruma, Mayu Ito, Akane Fukuda, Satoshi Kishimoto, Akihiro Taguchi, Kentaro Takayama, Atsuhiko Taniguchi, Yuji Ito and Yoshio Hayashi, Synthesis and structure-activity relationship studies of IgG-binding peptides focused on the C-terminal histidine residue, Med. Chem. Commun. (2019) 10, 1789-1795.
  6. Keisuke Hamada, Noriko Omura, Akihiro Taguchi, Alireza Baradaran-Heravi, Masaya Kotake, Misaki Arai, Kentaro Takayama, Atsuhiko Taniguchi, Michel Roberge, Yoshio Hayashi, New negamycin-based potent readthrough derivative effective against TGA-type nonsense mutations, ACS Med. Chem. Lett. (2019) 10, 1450-1456.
  7. Keisuke Hamada, Akari Naito, Yu Hamaguchi, Yu Kanesaki, Koji Kasahara, Akihiro Taguchi, Noriko Omura, Yoshio Hayashi, Takeo Usui, Ubr1p-cup9p-ptr2p pathway involves in the sensitivity to readthrough compounds negamycin derivatives in budding yeast, Biosci. Biotechnol. Biochem. (2019) 83, 1889-1892.

2018年の業績

  1. Kyohei Muguruma, Takuya Shirasaka, Daichi Akiyama, Kentarou Fukumoto, Akihiro Taguchi, Kentaro Takayama, Atsuhiko Taniguchi, Yoshio Hayashi, An efficient method for the conjugation of hydrophilic and hydrophobic components by solid-phase-assisted disulfide ligation, Angew. Chem. Int. Ed. (2018) 57, 2170-2173.
  2. Takumi Chinen, Keisuke Hamada, Akihiro Taguchi, Yukihiro Asami, Kazuro Shiomi, Yoshio Hayashi and Takeo Usui, Multidrug Sensitive Yeast Strains, Useful Tools for Chemical Genetics, The Yeast Role in Medical Applications, Waleed Mohamed Hussain Abdulkhair, (2018) 29-51.
  3. Akihiro Taguchi, Keisuke Hamada, Yoshio Hayashi, Chemotherapeutics Overcoming Nonsense Mutation-associated Genetic Diseases: Medicinal Chemistry of Negamycin, J. Antibiot. (2018) 71, 205-214.
  4. Yoshinari Wakiyama, Ko Kumura, Eijiro Umemura, Satomi Masaki, Kazutaka Ueda, Yasuo Sato, Yoko Hirai, Yoshio Hayashi, and Keiichi Ajito, Synthesis and SARs of Novel Lincomycin Derivatives Part 5: Optimization of Lincomycin Analogs Exhibiting Potent Antibacterial Activities by Chemical Modification at the 6- and 7-Positions, J. Antibiot. (2018) 71, 298-317.
  5. Ryo Masuda, Risa Hayashi, Hiroshi Nose, Akihiro Taguchi, Yoshio Hayashi, Hiroyuki Yasui, and Takaki Koide, Development of a Carboplatin Derivative Conjugated with a Collagen-like Triple-helical Peptide, Future Med. Chem. (2018) 10, 619-629.
  6. Yan Cui, Cedric Rentier, Akihiro Taguchi, Kentaro Takayama, Atsuhiko Taniguchi, Yoshio Hayashi, 4-Fluorophenyl 3-nitro-2-pyridinesulfenate as a practical protecting agent for amino acids, J. Pept. Sci. (2018) 24, e3070.
  7. Koushi Hidaka, Tooru Kimura, Rajesh Sankaranarayanan, Jun Wang, Keith F. McDaniel, Dale J. Kempf, Masanori Kameoka, Motoyasu Adachi, Ryota Kuroki, Jeffrey-Tri Nguyen, Yoshio Hayashi, and Yoshiaki Kiso, Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine, J. Med. Chem. (2018), 61, 5138-5153.
  8. Yuki Okada, Kaori Okubo, Keisuke Ikeda, Yoshiaki Yano, Masaru Hoshino, Yoshio Hayashi, Yoshiaki Kiso, Hikari Itoh-Watanabe, Akira Naito, and Katsumi Matsuzaki, Toxic Amyloid Tape: A Novel Mixed Antiparallel/Parallel β-Sheet Structure Formed by Amyloid β-Protein on GM1 Clusters, ACS Chem. Neurosci. (2019) 10, 563-572.
  9. 田口 晃弘、小谷 明、袴田 秀樹、林 良雄、環状ペプチド合成に有用なジスルフィド形成試薬Npys-OMeの創製、和光純薬時報, Vol. 86, 2-5, 富士フィルム和光純薬株式会社, 2018.
  10. 林 良雄、髙山 健太郎、ペプチドの構造制御による筋肉増強薬をめざしたマイオスタチン阻害ペプチドの創製、生命機能に迫る分子化学、CSJ Curr. Rev. 30(日本化学会編)、化学同人、2018.
  11. 伊東 祐二、金山 洋介、林 良雄、親和性ペプチドを用いた部位特異的修飾法による抗体の高機能化技術、実験医学(津本浩平編)、Vol. 36, No. 11(7月号)、羊土社、2018.
  12. 林 良雄、薬の本質を理解する「臨床医薬品化学」を拓く、ファルマシア(日本薬学会編)、Vol.54, No. 12, 日本薬学会、2018.

2017年の業績

  1. Tomo Asari, Kentaro Takayama, Akari Nakamura, Takahiro Shimada, Akihiro Taguchi and Yoshio Hayashi, Structural basis for the effective myostatin inhibition of the mouse myostatin prodomain–derived minimum peptide, ACS Med. Chem. Lett. 8, 113-117 (2017).
  2. Hisatoshi Shida, Hiroyuki Okada, Hajime Suzuki, Xianfeng Zhang, Jing Chen, Yasuko Tsunetsugu-Yokota, Yuetsu Tanaka, Fumika Yakushiji and Yoshio Hayashi, HIV-1 susceptibility of transgenic rat-derived primary macrophage/T cells and a T cell line that express human receptors, CyclinT1 and CRM1 genes, Genes Cells 22, 424-435 (2017).
  3. Chihiro Uchiyama, Yukari Miyadera, Yoshio Hayashi and Fumika Yakushiji, One-pot selective synthesis of 2,3-dihydro-4H-furo[3,2-c]coumarins by palladium-catalyzed silver-assisted propargylation/intramolecular 5-exo-dig cyclization,ChemistrySelect 2, 3794-3798 (2017).
  4. Akihiro Taguchi, Kiyotaka Kobayashi, Akira Kotani, Kyohei Muguruma, Misaki Kobayashi, Kentarou Fukumoto, Kentaro Takayama, Hideki Hakamata and Yoshio Hayashi, 3-Nitro-2-pyridinesulfenates as efficient solution and solid-phase disulfide bond forming agents, Chem. Eur. J. 23, 8262-8267 (2017).
  5. Cédric Rentier, Kentarou Fukumoto, Akihiro Taguchi and Yoshio Hayashi, The 3-nitro-2-pyridinesulfenyl group: synthesis and applications to peptide chemistry, J. Pept. Sci. 23, 496-504 (2017).
  6. Fumika Yakushiji, Kyohei Muguruma, Yoshiki Hayashi, Takuya Shirasaka, Ryosuke Kawamata, Hironari Tanaka, Yushi Yoshiwaka, Akihiro Taguchi, Kentaro Takayama, and Yoshio Hayashi, Click strategy using disodium salts of amino acids improves the water solubility of plinabulin and KPU-300, Bioorg. Med. Chem. 25, 3623-3630 (2017).
  7. Kentaro Takayama, Kenji Mori, Akiko Tanaka, Erina Nomura, Yuko Sohma, Miwa Mori, Akihiro Taguchi, Atsuhiko Taniguchi, Toshiyasu Sakane, Akira Yamamoto, Naoto Minamino, Mikiya Miyazato, Kenji Kangawa, and Yoshio Hayashi, Discovery of a human neuromedin U receptor 1-selective hex-apeptide agonist with enhanced serum stability, J. Med. Chem. 60, 5228-5234 (2017).
  8. Kentaro Takayama, Cédric Rentier, Tomo Asari, Akari Nakamura, Yusuke Saga, Takahiro Shimada, Kei Nirasawa, Eri Sasaki, Kyohei Muguruma, Akihiro Taguchi, Atsuhiko Taniguchi, Yoichi Negishi, and Yoshio Hayashi,  Development of potent myostatin inhibitory peptides through hydrophobic residue-directed structural modification, ACS Med. Chem. Lett. 8, 751-756 (2017).
  9. Weidong Zhang, Hideyuki Sakoda, Ayako Miura, Koichiro Shimizu, Kenji Mori, Mikiya Miyazato, Kentaro Takayama, Yoshio Hayashi, Masamitsu Nakazato, Neuromedin U suppresses glucose-stimulated insulin secretion in pancreatic β cells, Biochem. Biophys. Res. Commun. 493, 677-683 (2017).
  10. Akihiro Taguchi, Keisuke Hamada, Masataka Shiozuka, Misaki Kobayashi, Saori Murakami, Kentaro Takayama, Atsuhiko Taniguchi, Takeo Usui, Ryoichi Matsuda, and Yoshio Hayashi, Structure-activity relationship study of leucyl-3-epi-deoxynegamycin for potent premature termination codon readthrough, ACS Med. Chem. Lett. 8, 1060-1065 (2017).
  11. 六車 共平,林 良雄,ペプチド-薬物複合体の効率的な合成法の開発,Biophilia電子版21号, 特集 論理薬科学-創薬の基盤,ビオフィリア編集委員会,6, 62-68 (2017)
  12. 伊東 祐二 ,金山 洋介,林 良雄,六車 共平,抗体部位特異的修飾法を用いた放射性医薬品の開発,Isotope News (Vol. 755) 2018年 2月号, 22-24 (2017).

2016年の業績

  1. Kentaro Takayama, Akari Nakamura, Cédric Rentier, Yusaku Mino, Tomo Asari, Yusuke Saga, Akihiro Taguchi, Fumika Yakushiji and Yoshio Hayashi, Effect of N-terminal acylation on the activity of myostatin inhibitory peptides, ChemMedChem 11, 845-849 (2016).
  2. Kyohei Muguruma, Fumika Yakushiji, Ryosuke Kawamata, Daichi Akiyama, Risako Arima, Takuya Shirasaka, Yamato Kikkawa, Akihiro Taguchi, Kentaro Takayama, Takeshi Fukuhara, Tetsuro Watabe, Yuji Ito, Yoshio Hayashi, Novel hybrid compound of a plinabulin prodrug with an IgG binding peptide for generating a tumor selective non-covalent-type antibody-drug conjugate, Bioconjugate Chem. 27, 1606-1613 (2016).
  3. Kentaro Takayama, Akihiro Taguchi, Fumika Yakushiji, and Yoshio Hayashi, Identification of a degrading enzyme in human serum that hydrolyzes a C-terminal core sequence of neuromedin U, Biopolymers 106, 440-445 (2016).
  4. Thanigaimalai Pillaiyar, Manoj Manickam, Vigneshwaran Namasivayam, Yoshio Hayashi, and Sang-Hun Jung, An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy, J. Med. Chem. 59, 6595-6628 (2016).
  5. 田口 晃弘、福元 謙太郎、林 良雄、固相担持型ジスルフィド形成試薬の創製とその応用、化学工業、化学工業、2016、67、853-860.
  6. 髙山 健太郎、林 良雄、マウスマイオスタチンプロドメイン配列に由来するマイオスタチン阻害ペプチドの発見、Jasco Report、ジャスコレポート社、2016、58、6-11.

2015年の業績

  1. Kentaro Takayama, Yuri Noguchi, Shin Aoki, Shota Takayama, Momoko Yoshida, Tomo Asari, Fumika Yakushiji, Shin-ichiro Nishimatsu, Yutaka Ohsawa, Fumiko Itoh, Yoichi Negishi, Yoshihide Sunada, and Yoshio Hayashi, Identification of the minimum peptide from mouse myostatin prodomain for human myostatin inhibition, J. Med. Chem. 58, 1544-1549 (2015).
  2. Akihiro Taguchi, Kentarou Fukumoto, Yuya Asahina, Akihiro Kajiyama, Shunsuke Shimura, Keisuke Hamada, Kentaro Takayama, Fumika Yakushiji, Hironobu Hojo and Yoshio Hayashi, 3-Nitro-2-pyridinesulfenyl-mediated solid-phase disulfide ligation in the synthesis of disulfide bond-containing cyclic peptides, Org. Biomol. Chem. 13, 3186-3189 (2015).
  3. Kentaro Takayama, Kenji Mori, Yuko Sohma, Koji Taketa, Akihiro Taguchi, Fumika Yakushiji, Naoto Minamino, Mikiya Miyazato, Kenji Kangawa, and Yoshio Hayashi, Discovery of potent hexapeptide agonists to human neuromedin U receptor 1 and identification of their serum metabolites, ACS Med. Chem. Lett. 6, 302-307(2015).
  4. Keisuke Hamada, Akihiro Taguchi, Masaya Kotake, Suguru Aita, Saori Murakami, Kentaro Takayama, Fumika Yakushiji, and Yoshio Hayashi, Structure-activity relationship studies of 3-epi-deoxynegamycin derivatives as potent readthrough drug candidates, ACS Med. Chem. Lett. 6, 689-694 (2015).
  5. Yutaka Ohsawa, Kentaro Takayama, Shin-ichiro Nishimatsu, Tadashi Okada, Masahiro Fujino, Yuta Fukai, Tatsufumi Murakami, Hiroki Hagiwara, Fumiko Itoh, Kunihiro Tsuchida, Yoshio Hayashi, and Yoshihide Sunada, The inhibitory core of the myostatin prodomain: its interaction with both type I and type II membrane receptors and potential to treat muscle atrophy, PLoS One 10, e0133713 (2015).
  6. Takumi Chinen, Peng Liu, Shuya Shioda, Judith Pagel, Berati Cerikan, Tien-chen Lin, Oliver Gruss, Yoshiki Hayashi, Haruka Takeno, Tomohiro Shima, Yasushi Okada, Ichiro Hayakawa, Yoshio Hayashi, Hideo Kigoshi, Takeo Usui, and Elmar Schiebel, The γ-tubulin-specific inhibitor gatastatin reveals temporal requirements of microtubule nucleation during the cell cycle, Nat Commun. 6, 8722 (2015); doi: 10.1038/ncomms9722.
  7. Kentarou Fukumoto, Akihiro Kajiyama, Shunsuke Shimura, Koji Taketa, Shinichiro Kimura, Akihiro Taguchi, Kentaro Takayama, Fumika Yakushiji, and Yoshio Hayashi, Development of a thiol selective solid-supported oligoarginine-conjugating reagent KSH-2, Aisan J . Org. Chem. 4, 1030-1033 (2015).

2014年の業績

  1. Kentaro Takayama, Development of an oligoarginine peptide displaying rapid cell penetration for improved intestinal absorption, YAKUGAKU ZASSHI 134, 55-61 (2014).
  2. Fumika Yakushiji, Masako Haramo, Yukari Miyadera, Chihiro Uchiyama, Kentaro Takayama, and Yoshio Hayashi, Palladium Catalyzed C3-Selective mono-Arylation of 4-Hydroxycoumarin, Tetrahedron Lett. 55, 3316-3318 (2014).
  3. Akihiro Taguchi, Keisuke Hamada, Masaya Kotake, Masataka Shiozuka, Hidemasa Nakaminami, Thanigaimalai Pillaiyar, Kentaro Takayama, Fumika Yakushiji, Norihisa Noguchi, Takeo Usui, Ryoichi Matsuda, and Yoshio Hayashi, Discovery of natural products possessing selective eukaryotic readthrough activity: 3-epi-deoxynegamycin and its leucine adduct, ChemMedChem 9, 2233-2237(2014).
  4. Kentaro Takayama, Kenji Mori, Koji Taketa, Akihiro Taguchi, Fumika Yakushiji, Naoto Minamino, Mikiya Miyazato, Kenji Kangawa, and Yoshio Hayashi, Discovery of selective hexapeptide agonists to human neuromedin U receptors types 1 and 2, J. Med. Chem. (2014) 57, 6583-6593.
  5. Yoshiki Hayashi, Haruka Takeno, Takumi Chinen, Kyohei Muguruma, Kohei Okuyama, Akihiro Taguchi, Kentaro Takayama, Fumika Yakushiji, Masahiko Miura, Takeo Usui and Yoshio Hayashi, Development of a new benzophenone-diketopiperazine-type potent anti-microtubule agent possessing a 2-pyridine structure, ACS Med. Chem. Lett. 5, 1094-1098 (2014).
  6. 林 良雄、山本 剛史、小岩井 勇児、SARSコロナウイルスプロテアーゼ阻害剤の創薬、遺伝子医学MOOK版「次世代ペプチド医薬創製」(赤路健一編)、株式会社メディカル ドゥ、pp39 (2014).
  7. 田口 晃弘、濱田 圭佑、林 良雄、リードスルー機能に着目した遺伝性疾患治療薬の創製研究、ファルマシア(最前線)、2014年10月号.

2013年の業績

  1. Sho Konno, Kiyohiko Nakada, Pillaiyar Thanigaimalai, Rie Kakiuchi, Takehito Yamamoto, Kentaro Takayama, Yuri Yamazaki, Fumika Yakushiji, Kenichi Akaji, Yoshiaki Kiso, Yuko Kawasaki, Ernesto Freire, and Yoshio Hayashi, Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety, Bioorg. Med. Chem. 21, 412-424 (2013).
  2. Fumika Yakushiji, Yuko Miyamoto, Yuki Kunoh, Reiko Okamoto, Hidemasa Nakaminami, Yuri Yamazaki, Norihisa Noguchi, Yoshio Hayashi, Novel Hybrid-Type Antimicrobial Agents Targeting the Switch Region of Bacterial RNA Polymerase, ACS Med. Chem. Lett. 4, 220-224 (2013).
  3. Pillaiyar Thanigaimalai, Sho Konno, Takehito Yamamoto, Yuji Koiwai, Akihiro Taguchi, Kentaro Takayama, Fumika Yakushiji, Kenichi Akaji, Yoshiaki Kiso, Yuko Kawasaki, Shen-En Chen, Aurash Naser-Tavakolian, Arne Schön, Ernesto Freire, and Yoshio Hayashi, Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: Structure–activity relationship study, Eur. J. Med. Chem. 65, 436-447 (2013).
  4. 薬師寺文華、バンコマイシンの部位選択的脱酸素化が示す立体配座効果、ファルマシア(トピックス)、2013年1月号.
  5. Yoshio Hayashi, Yuri Yamazaki-Nakamura, and Fumika Yakushiji, Medicinal chemistry and chemical biology of diketopiperazine-type anti-microtubule and vascular disrupting agents, Chem. Pharm. Bull. (Review) 61, 889-901(2013).
  6. Pillaiyar Thanigaimalai, Sho Konno, Takehito Yamamoto, Yuji Koiwai, Akihiro Taguchi, Kentaro Takayama, Fumika Yakushiji, Kenichi Akaji, Shen-En Chen, Aurash Naser-Tavakolian, Arne Schӧn, Ernesto Freire, and Yoshio Hayashi, Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies, Eur. J. Med. Chem. 68, 372-384(2013).

2012年の業績

  1. Yuri Yamazaki, Makiko Sumikura, Yurika Masuda, Yoshiki Hayashi, Hiroyuki Yasui, Yoshiaki Kiso, Takumi Chinen, Takeo Usui, Fumika Yakushiji, Barbara Potts, Saskia Neuteboom, Michael Palladino, George Kenneth Lloyd and Yoshio Hayashi, Synthesis and structure-activity relationships of benzophenone-bearing diketopiperazine-type anti-microtubule agents, Bioorg. Med. Chem., 20, 4279-4289 (2012).
  2. Kentarou Fukumoto, Kumi Adachi, Akihiro Kajiyama, Yuri Yamazaki, Fumika Yakushiji, Yoshio Hayashi, Development of a solid-supported biotinylation reagent for efficient biotin labeling of SH groups on small molecules, Tetrahedron Lett., 53, 535–538 (2012).
  3. Yuri Yamazaki, Koji Tanaka, Benjamin Nicholson, Gordafaried Deyanat-Yazdi, Barbara Potts, Tomoko Yoshida, Akiko Oda, Takayoshi Kitagawa, Sumie Orikasa, Yoshiaki Kiso, Hiroyuki Yasui, Miki Akamatsu, Takumi Chinen, Takeo Usui, Yuki Shinozaki, Fumika Yakushiji, Brian R. Miller, Saskia Neuteboom, Michael Palladino, Kaneo Kanoh, George Kenneth Lloyd, and Yoshio Hayashi, Synthesis and Structure–Activity Relationship Study of Antimicrotubule Agents Phenylahistin Derivatives with a Didehydropiperazine-2,5-dione Structure, J. Med. Chem., 55, 1056–1071 (2012).
  4. Akihiro Taguchi, Shigenobu Nishiguchi, Masataka Shiozuka, Takao Nomoto, Mayuko Ina, Shouta Nojima, Ryoichi Matsuda, Yoshiaki Nonomura, Yoshiaki Kiso, Yuri Yamazaki, Fumika Yakushiji, and Yoshio Hayashi, Negamycin Analogue with Readthrough-Promoting Activity as a Potential Drug Candidate for Duchenne Muscular Dystrophy, ACS Med. Chem. Lett., 3, 118–122 (2012).
  5. Fumika Yakushiji, Hironari Tanaka, Kyohei Muguruma, Takahiro Iwahashi, Yuri Yamazaki, and Yoshio Hayashi, Prodrug Study of Plinabulin using a Click Strategy Focused on the Effects of a Replaceable Water-solubilizing Moiety, Chem. Pharm. Bull., 60, 877–881 (2012).
  6. Asumi Honda-Uezono, Atsushi Kaida, Yasuyuki Michi, Kiyoshi Harada, Yoshiki Hayashi, Yoshio Hayashi, and Masahiko Miura, Unusual expression of red fluorescence at M phase induced by anti-microtubule agents in HeLa cells expressing the fluorescent ubiquitination-based cell cycle indicator (Fucci), Biochem. Biophys. Res. Commun. 428, 224-229 (2012).
  7. 山崎 有理、放線菌由来抗がん剤デュオカルマイシン類縁体の新たな標的分子、ファルマシア(トピックス、10月号)、48、pp978 (2012).
  8. 山崎 有理、林 良雄、環状ジペプチド型抗がん剤の創薬研究とケミカルバイオロジー展開,遺伝子医学MOOK 21号「最新ペプチド合成技術とその創薬研究への応用」株式会社メディカル ドゥ、260-266 (2012).
  9. 髙山 健太郎、二木 史朗、林 良雄、山本 昌、自己分解型リンカーを用いたオリゴアルギニン修飾による薬物の消化管吸収性の改善、難吸収性薬物の吸収性改善と新規投与製剤の開発 (山本昌編)、119-125、シーエムシー出版 (2012)
  10. 髙山 健太郎、林 良雄、ペプチドとくすり、ペプチド医薬の最前線 (向井秀仁、木曽良明編)、9-14、シーエムシー出版 (2012)

2011年度研究室の業績

原著

1) Fumika Yakushiji, Hironari Tanaka, Kyohei Muguruma, Takahiro Iwahashi, Yuri Yamazaki, and Yoshio Hayashi, Water-Soluble Prodrug of Antimicrotubule Agent Plinabulin: Effective Strategy with Click Chemistry, Chem. Eur. J., 17, 12587–12590 (2011)

2) Kentarou Fukumoto, Kumi Adachi, Akihiro Kajiyama, Yuri Yamazaki, Fumika Yakushiji, Yoshio Hayashi, Development of a solid-supported biotinylation reagent for efficient biotin labeling of SH groups on small molecules, Tetrahedron Lett., 53, 535–538 (2012)

3) Yuri Yamazaki, Koji Tanaka, Benjamin Nicholson, Gordafaried Deyanat-Yazdi, Barbara Potts, Tomoko Yoshida, Akiko Oda, Takayoshi Kitagawa, Sumie Orikasa, Yoshiaki Kiso, Hiroyuki Yasui, Miki Akamatsu, Takumi Chinen, Takeo Usui, Yuki Shinozaki, Fumika Yakushiji, Brian R. Miller, Saskia Neuteboom, Michael Palladino, Kaneo Kanoh, George Kenneth Lloyd, and Yoshio Hayashi, Synthesis and Structure–Activity Relationship Study of Antimicrotubule Agents Phenylahistin Derivatives with a Didehydropiperazine-2,5-dione Structure, J. Med. Chem., 55, 1056–1071 (2012)

4) Akihiro Taguchi, Shigenobu Nishiguchi, Masataka Shiozuka, Takao Nomoto, Mayuko Ina, Shouta Nojima, Ryoichi Matsuda, Yoshiaki Nonomura, Yoshiaki Kiso, Yuri Yamazaki, Fumika Yakushiji, and Yoshio Hayashi, Negamycin Analogue with Readthrough-Promoting Activity as a Potential Drug Candidate for Duchenne Muscular Dystrophy, ACS Med. Chem. Lett., 3, 118–122 (2012)

5) Henri-Obadja Kumada, Jeffrey-Tri Nguyen, Taeko Kakizawa, Koushi Hidaka, Tooru Kimura, Yoshio Hayashi and Yoshiaki Kiso, Development of [Ile40]HTLV-I protease inhibition assay using novel fluorogenic and chromogenic substrate, J.Pept.Sci., 17, 569–575 (2011)

総説・著書

1) 薬師寺文華
“温故知新:アミド結合形成の新展開 ”
有機合成化学協会誌, 69, 715-716 (2011)

2) 山崎 有理,林 良雄
環状ジペプチド型抗がん剤の創薬研究とケミカルバイオロジー展開
遺伝子医学MOOK 21号「最新ペプチド合成技術とその創薬研究への応用」、株式会社メディカル ドゥ、260-266 (2012) 

2010年度研究室の業績

原著

1)  Yuri Yamazaki, Makiko Sumikura, Koushi Hidaka, Hiroyuki Yasui, Yoshiaki Kiso, Fumika Yakushiji, and Yoshio Hayashi, Anti-microtubule ‘Plinabulin’ Chemical Probe KPU-244-B3 Labeled Both α-and β-Tubulin, Bioorg. Med. Chem., 18, 3169-3174(2010)

2) Noriko Shimizu, Shigeru Sugiyama, Mihoko Maruyama, Yoshinori Takahashi, Motoyasu Adachi, Taro Tamada, Koushi Hidaka, Yoshio Hayashi, Tooru Kimura, Yoshiaki Kiso, Hiroaki Adachi, Kazufumi Takano, Satoshi Murakami, Tsuyoshi Inoue, Ryota Kuroki, Yusuke Mori, and Hiroyoshi Matsumura, Crystal Growth Procedure of HIV-1 Protease-inhibitor KNI-272 Complex for Neutron Structural Analysis at 1.9 A Resolution, Cryst. Growth Des., 10, 2990-2994(2010)

3) Yuri Yamazaki, Yui Kido, Koushi Hidaka, Hiroyuki Yasui, Yoshiaki Kiso, Fumika Yakushiji, and Yoshio Hayashi, Tubulin Photoaffinity Labeling Study with a Plinabulin Chemical Probe Possessing a Biotin Tag at the Oxazole, Bioorg. Med. Chem., 19, 595-602(2011)

総説・著書

1) 木曽 良明,林 良雄,相馬 洋平,日高 興士
生物分子システムを基盤とする統合創薬科学
MEDCHEM NEWS, 20, 2-8(2010)

2009年度研究室の業績

原著

1) Fumika Yakushiji, Jacques Maddaluno, Masahiro Yoshida, and Kozo Shishido, Diastereoselective Construction of Substituted Tetrahydropyrans Using an Intramolecular Oxy-Michael Strategy, Tetrahedron Lett., 50, 1504-1506 (2009)

2) Atsuhiko Taniguchi, Youhei Sohma, Yuta Hirayama, Hidehito Mukai, Tooru Kimura, Yoshio Hayashi, Katsumi Matsuzaki, Yoshiaki Kiso, “Click Peptide”: pH-triggered in Situ Production and Aggregation of Monomer Aβ1-42, ChemBioChem 10, 710-715 (2009)

3) Motoyasu Adachi, Takashi Ohhara, Kazuo Kurihara, Taro Tamada, Eijiro Honjo, Nobuo Okazaki, Shigeki Arai, Yoshinari Shoyama, Kaname Kimura, Hiroyoshi Matsumura, Shigeru Sugiyama, Hiroaki Adachi, Kazufumi Takano, Yusuke Mori, Koushi Hidaka, Tooru Kimura, Yoshio Hayashi, Yoshiaki Kisoand Ryota Kuroki, Structure of HIV-1 Protease in Complex with Potent Inhibitor KNI-272 Determined by High-resolution X-ray and Neutron Crystallography, Proc. Natl. Acad. Sci. USA, 106, 4641-4646 (2009)

4) Yuri Yamazaki, Yuki Mori, Akiko Oda, Yuka Okuno, Yoshiaki Kiso, and Yoshio Hayashi, Acid Catalyzed Monodehydro-2,5-diketopiperazine Formation from N-α-ketoacyl Amino Acid Amides, Tetrahedron, 65, 3688-3694 (2009)

5) Thomas Regnier, Diganta Sarma, Koushi Hidaka, Usman Bacha, Ernesto Freire, Yoshio Hayashi, and Yoshiaki Kiso, New Developments for the Design, Synthesis and Biological Evaluation of Potent SARS-CoV 3CLproInhibitors, Bioorg. Med. Chem. Lett., 19, 2722-2727 (2009)

6) Koushi Hidaka, Tooru Kimura, Hamdy M. Abdel-Rahman, Jeffrey-Tri Nguyen, Keith F. McDaniel, William E. Kohlbrenner, Akhteruzzaman Molla, Motoyasu Adachi, Taro Tamada, Ryota Kuroki, Noriko Katsuki, Yoshiaki Tanaka, Hikaru Matsumoto, Jun Wang, Yoshio Hayashi, Dale J. Kempfand Yoshiaki Kiso, Small-Sized Human Immunodeficiency Virus Type-1 Protease Inhibitors Containing Allophenylnorstatine to Explore the S2’ Pocket, J. Med. Chem., 52, 7604–7617 (2009)

7) Shigenobu Nishiguchi, Magne O. Sydnes, Akihiro Taguchi, Thomas Regnier, Tetsuya Kajimoto, Manabu Node, Yuri Yamazaki, Fumika Yakushiji, Yoshiaki Kiso, and Yoshio Hayashi, Total Synthesis of (+)-Negamycin and Its 5-epi-derivative, Tetrahedron, 66, 314-320 (2010)

2008年度研究室の業績

原著

1) Truncation and Non-natural Amino Acid Substitution Studies on HTLV-I Protease Hexapeptidic Inhibitors, Bioorg. Med. Chem. Lett., 18, 366-370 (2008)
Jeffrey-Tri Nguyen*1, Meihui Zhang*1,2, Henri-Obadja Kumada*1, Ayako Itami*1, Keiji Nishiyama*1, Tooru Kimura*1, Maosheng Cheng*2, Yoshio Hayashi, Yoshiaki Kiso*1
  *1 Kyoto Pharmaceutical University, *2 Shenyang Pharmaceutical University

2) Fmoc-based Solid Phase Chemical Synthesis of 71-meric Neuregulin 1-beta1, an Epidermal Growth Factor-like Domain, J. Peptide Sci., 14, 261-266 (2008)
Taeko Kakizawa*, Shizuyo Koide-Yoshida*, Tooru Kimura*, Hiromasa Uchimura*, Yoshio Hayashi, Kazuki Saito*, Yoshiaki Kiso*
  * Kyoto Pharmaceutical University

3) BACE1 Inhibitors: Optimization by Replacing the P1′ Residue with Non-acidic Moiety, Bioorg. Med. Chem. Lett., 18, 1649-1653, (2008)
Yoshio Hamada*1, Hamdy Abdel-Rahman*1, Abdellah Yamani*1, Jeffrey-Tri Nguyen*1, Monika Stochaj*1, Koushi Hidaka*1, Tooru Kimura*1, Yoshio Hayashi, Kazuki Saito*1, Shoichi Ishiura*2 and Yoshiaki Kiso*1
  *1 Kyoto Pharmaceutical University, *2 University of Tokyo

4) Novel Non-peptidic and Small-sized BACE1 Inhibitors, Bioorg. Med. Chem. Lett., 18, 1654-1658, (2008)
Yoshio Hamada*1, Hiroko Ohta*1, Naoko Miyamoto*1, Ryoji Yamaguchi*1, Abdellah Yamani*1, Koushi Hidaka*1, Tooru Kimura*1, Kazuki Saito*1, Yoshio Hayashi, Shoichi Ishiura*2 and Yoshiaki Kiso*1
  *1 Kyoto Pharmaceutical University, *2 University of Tokyo

5) Combination of Non-natural D-Amino Acid Derivatives and Allophenylnorstatine-Dimethylthioproline Scaffold in HIV Protease Inhibitors Have High Efficacy in Mutant HIV, J. Med. Chem., 51, 2992-3004, (2008)
Shingo Nakatani*1, Koushi Hidaka*1, Ei’ichi Ami*1, Koichiro Nakahara*1, Akihiko Sato*2, Jeffrey-Tri Nguyen*1, Yoshio Hamada*1, Yasuko Hori*1, Nobuyuki Ohnishi*1, Akinori Nagai*1, Tooru Kimura*1, Yoshio Hayashi and Yoshiaki Kiso*1
  *1 Kyoto Pharmaceutical University *2 Shionogi Co. Ltd

6) Efficient Total Synthesis of (+)-Negamycin, a Potential Chemotherapeutic Agent for Genetic Diseases, Chem. Comm., 2379-2381, (2008)
Yoshio Hayashi, Thomas Regnier*1, Shigenobu Nishiguchi*1, Magne O. Sydnes*1, Daisuke Hashimoto*1, Junya Hasegawa*1, Takahiro Katoh*1, Tetsuya Kajimoto*1, Masataka Shiozuka*2, Ryoichi Matsuda*2, Manabu Node*1 and Yoshiaki Kiso*1
   *1 Kyoto Pharmaceutical University, *2 University of Tokyo

7) Development of Novel Water-soluble Photocleavable Protective Group and Its Application for Design of Photoresponsive Paclitaxel Prodrugs, Bioorg. Med. Chem., 16, 5389-5397, (2008)
Mayo Noguchi*1, Mariusz Skwarczynski*1, Halan Prakash*2, Shun Hirota*2, Tooru Kimura*1, Yoshio Hayashi and Yoshiaki Kiso*1
  *1 Kyoto Pharmaceutical University, *2 Nara Institute of Science and Technology

8) Synthesis and Activity of Tetrapeptidic HTLV-I Protease Inhibitors Possessing Different P3-cap Moieties, Bioorg. Med. Chem., 16, 5795-5802, (2008)
J Meihui Zhang*1,2, Jeffrey-Tri Nguyen*1, Henri-Obadja Kumada*1, Tooru Kimura*1, Maosheng Cheng*2, Yoshio Hayashi and Yoshiaki Kiso*1
  *1 Kyoto Pharmaceutical University, *2 Shenyang Pharmaceutical University

9) Design, Synthesis and Biophysical Properties of a Helical A 1-42 Analog: Inhibition of Fibrillogenesis and Cytotoxicity, Biochem. Biophys. Res. Commun., 371, 777-780, (2008)
Katsumi Matsuzaki*1, Takuma Okada*1, Miho Tsukuda*1, Keisuke Ikeda*1, Youhei Sohma*2, Yousuke Chiyomori*2, Atsuhiko Taniguchi*2, Setsuko Nakamura*2, Nui Ito*2, Yoshio Hayashi and Yoshiaki Kiso*2
  *1 Kyoto University, *2 Kyoto Pharmaceutical University

10) Locking the Two Ends of Tetrapeptidic HTLV-I Protease Inhibitors Inside the Enzyme, Bioorg. Med. Chem., 16, 6880-6890, (2008)
Meihui Zhang*1,2, Jeffrey-Tri Nguyen*1, Henri-Obadja Kumada*1, Tooru Kimura*1, Maosheng Cheng*2, Yoshio Hayashi and Yoshiaki Kiso*1
  *1 Kyoto Pharmaceutical University, *2 Shenyang Pharmaceutical University

11) Metabolism of Phenylahistin Enantiomers by Cytochromes P450: a Possible Explanation for their Different Cytotoxicity, Drug Metabolism and Disposition, 36, 2381-2392, (2008)
Lionel Perrin*1, Caroline Aninat*2, Veronique Hamon*1, Yoshio Hayashi, Catherine Abadie*3, Bruno Heyd*4, Francois Andre*1, Marcel Delaforge*1
  *1 CEA-CNRS-URA 2096, *2Université de Rennes I, *3 Kaly Cell Besançon, *4 C. H. U. de Besançon Hôpital Jean Minjoz

12) Crystallization and Preliminary Neutron Diffraction Studies of HIV-1 Protease Cocrystallized with Inhibitor KNI-272, Acta Cryst. F, 64, 1003-1006, (2008)
Hiroyoshi Matsumura*1,2,3, Motoyasu Adachi*4, Shigeru Sugiyama*1,3, Shino Okada*3, Megumi Yamakami*3, Taro Tamada*4, Koushi Hidaka*5, Yoshio Hayashi, Tooru Kimura*5, Yoshiaki Kiso*5, Tomoya Kitatani*1,3, Sho Maki*1,3, Hiroshi Y. Yoshikawa*1,3, Hiroaki Adachi*1,2,3, Kazufumi Takano*1,2,3, Satoshi Murakami*2,3,6, Tsuyoshi Inoue*1,2,3, Ryota Kuroki*4 and Yusuke Mori*1,2,3
  *1 Osaka University, *2 SOSHO Inc., *3 CREST JST, *4 Kyoto Pharmaceutical University, *5 Tokyo Institute of Technology

13) Oligoarginine-based Prodrugs with Self-cleavable Spacers for Caco-2 Cell Permeation, Chem. Pharm. Bull., 56, 1515-1520, (2008)
Kentaro Takayama*1, Yuka Suehisa*2, Takuya Fujita*2, Jeffrey-Tri Nguyen*2, Shiroh Futaki*1, Akira Yamamoto*2, Yoshiaki Kiso*2 and Yoshio Hayashi
  *1 Kyoto University, *2 Kyoto Pharmaceutical University

14) D Antimalarial Activity Enhancement in Hydroxymethylcarbonyl (HMC) Isostere-based Dipeptidomimetics Targeting Malarial Aspartic Protease Plasmepsin, Bioorg. Med. Chem., 16, 10049-10060, (2008)
Koushi Hidaka*1, Tooru Kimura*1, Adam J.Ruben*2, Tsuyoshi Uemura*1, Mami Kamiya*1, Aiko Kiso*1, Tetsuya Okamoto*1, Yumi Tsuchiya*1, Yoshio Hayashi, Ernesto Freire*2 and Yoshiaki Kiso*1
  *1 Kyoto Pharmaceutical University, *2 John Hopkins University

15) Controlled Production of Amyloid  peptide from a Phototriggered, Water-soluble Precursor Click Peptide, ChemBioChem, 9, 3055-3065, (2008)
Atsuhiko Taniguchi*1, Mariusz Skwarczynski*1, Youhei Sohma*1, Takuma Okada*2, Keisuke Ikeda*2, Halan Prakash*3, Hidehito Mukai*1, Yoshio Hayashi, Tooru Kimura*1, Shun Hirota*3, Katsumi Matsuzaki*2 and Yoshiaki Kiso*1
  *1 Kyoto Pharmaceutical University, *2 Kyoto University, *3 Nara Institute of Science and Technology

16) Tubulin Photoaffinity Labeling with Biotin-tagged Derivatives of Potent Diketopiperazine Antimicrotubule Agents, ChemBioChem, 9, 3074-3081, (2008)
Yuri Yamazaki, Kyoko Kohno*1, Hiroyuki Yasui*1, Yoshiaki Kiso*1, Miki Akamatsu*2, Benjamin Nicholson*3, Gordafaried Deyanat-Yazdi*3, Saskia Neuteboom*3, Barbara Potts*3, G. Kenneth Lloyd*3 and Yoshio Hayashi
  *1 Kyoto Pharmaceutical University, *2 Kyoto University, *3 Nereus Pharmaceuticals Inc.

2007年度研究室の業績

原著

1) Youhei Sohma, Taku Yoshiya, Atsuhiko Taniguchi, Tooru Kimura, Yoshio Hayashi, Yoshiaki Kiso, Development of O-acyl isopeptide method, Biopolymers Peptide Science, 88, 253-262 (2007)

2) Koushi Hidaka, Tooru Kimura, Yumi Tsuchiya, Mami Kamiya, Adam J. Ruben, Ernesto Freire, Yoshio Hayashi, and Yoshiaki Kiso, Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II, Bioorg. Med. Chem. Lett., 17, 3048-3052 (2007)

3) Taku Yoshiya, Atsuhiko Taniguchi, Youhei Sohma, Fukue Fukao, Setsuko Nakamura, Naoko Abe, Nui Ito, Mariusz Skwarczynski, Tooru Kimura, Yoshio Hayashi, and Yoshiaki Kiso, “O-Acyl isopeptide method” for peptide synthesis: synthesis of forty kinds of “O-acyl isodipeptide unit” Boc-Ser/Thr(Fmoc-Xaa)-OH, Org. Biomol. Chem. 5, 1720-1730 (2007)

4) Tooru Kimura, Jeffrey-Tri Nguyen, Hikoichiro Maegawa, Keiji Nishiyama, Yasuhiro Arii, Yasuko Matsui, Yoshio Hayashi, and Yoshiaki Kiso, Chipping at large, potent human T-cell leukemia virus type 1 protease inhibitors to uncover smaller, equipotent inhibitors, Bioorg. Med. Chem. Lett., 17, 3276-3280 (2007)

5) Ei’ichi Ami, Koichiro Nakahara, Akihiko Sato, Jeffrey-Tri Nguyen, Koushi Hidaka, Yoshio Hamada, Shingo Nakatani, Tooru Kimura, Yoshio Hayashi, and Yoshiaki Kiso, Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating D-cysteine derivatives as P2/P3 moieties, Bioorg. Med. Chem. Lett., 17, 4213-4217 (2007)

6) Yoshio Hayashi, Kentaro Takayama, Yuka Suehisa, Takuya Fujita, Jeffrey-Tri Nguyen, Shiroh Futaki, Akira Yamamoto, and Yoshiaki Kiso, Development of oligoarginine-drug conjugates linked to new peptidic self-cleavable spacers toward effective intestinal absorption, Bioorg. Med. Chem. Lett., 17, 5129-5132 (2007)

7) Atsuhiko Taniguchi, Taku Yoshiya, Naoko Abe, Fukue Fukao, Youhei Sohma, Tooru Kimura, Yoshio Hayashi, and Yoshiaki Kiso, ‘O-Acyl isopeptide method’ for peptide synthesis: Solvent effects in the synthesis of Aß 1-42 isopeptide using ‘O-acyl isodipeptide unit’, J. Peptide Sci., 13, 868-874 (2007)

8) Hideki Abe, Kei-ichi Takaya, Kazuhiro Watanabe, Sakae Aoyagi, Chihiro Kibayashi, and Tadashi Katoh, Spirocyclization of an N-Acyliminium Ion with Substituted Pyridine: Synthesis of Tricyclic Spirolactams Possessing Pyridine or Pyridone Nucleus, Heterocycles74, 205-210 (2007)

9) Naoki Yamazaki, Takeshi Suzuki, Yuta Yoshimura, Chihiro Kibayashi, and Sakae Aoyagi, Asymmetric Synthesis of Stellettamides A and C, Heterocycles75, 285-290 (2008)